Winning in China’s Multi-Level Coverage Era
A Strategic Speaker Program for Global Pharma Teams
This 1.5-hour speaker program is both a strategic primer on China’s pricing and reimbursement system and a practical playbook to help global pharma capture upside opportunities while managing risks as the market shifts toward a multi-level coverage framework.
The idea grew out of two experiences: the C-List Masterclass series and my invitation to lecture at the University of Southern California on China’s new coverage framework. Both experiences made it clear how valuable a structured program could be — not only for knowledge, but also for bringing diverse stakeholders into the conversation at this critical turning point.
That’s really the goal: to help global teams align on what’s changing in China, and what may need to change internally to compete successfully in this new era.
What Past Participants Are Saying
C-List Masterclass
" It has been a delight to follow the C-List Masterclass. The timing is perfect, as it coincides with what may be a significant shift in how high-value medicines enter the Chinese market. The program allowed me to track developments in real time, with monitoring and analysis that highlighted both opportunities and remaining uncertainties. All in all, I would not have had it any other way—well done." — Director Access Policy, Top 10 Pharma
"It’s difficult to conduct desk research on China’s reimbursement policy changes, so joining the C-List Masterclass was a great way to access clear, structured information in English. The panel sessions with China-based experts were particularly insightful and valuable." — Head Global Market Access, Top Specialty Pharma
USC Lecture
"I went into this lecture knowing nothing about China’s healthcare system, but the discussion on the C-List and NRDL was truly enlightening from a future physician’s perspective." — Graduate Student, USC
"I really enjoyed how thorough and detailed the lecture was. Each slide was meaningful, deliberate, and tied to a clear learning goal. I learned so much in such a short time!" — Graduate Student, USC
“I learned a lot about China’s insurance system, which could really help me in the future as China continues to make progress. This session was truly insightful.” — Graduate Student, USC
“The case vignette was very helpful—it really pushed me to think strategically about the different factors involved in market access.” — Graduate Student, USC
"The lecture was very insightful, as the Chinese market is a completely new concept to me. Kelly was both knowledgeable and engaging in presenting the topic." — Graduate Student, USC
"I really liked the way Kelly explained the Chinese healthcare system and highlighted what could be improved in the future. She delivered a perfect lecture — I didn’t even expect that!” — Graduate Student, USC
About the Speaker
Kelly Ke
Founder, bizi LLC | Author, NRDL+ Executive Debrief
Kelly Ke is the founder of bizi, a consultancy helping life sciences companies navigate pricing, reimbursement, and access challenges both locally and globally. Operating at the intersection of health policy, commercial strategy, and execution, she helps senior leaders translate China’s evolving policy landscape into market-informed decisions.
Previously, Kelly spent a decade as an award-winning senior advisor in Deloitte’s US life sciences practice. She also authors the NRDL+ Executive Debrief, a widely followed newsletter read by executives across top global pharma, biotech, insurers, and leading universities.
Originally from Beijing, Kelly holds master’s degrees from USC and the University of Utah, and a postgraduate certificate in International HTA and Reimbursement from the University of Sheffield.
Contact
The speaker program is delivered as a standard, instructor-led mini-Masterclass for individual organizations, with a recording shared afterward for internal use. Reach out if you’d like details for your team.